PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT00392080
- Locations
- 🇺🇸
Pfizer Investigational Site, Chesapeake, Virginia, United States
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin Glargine (Lantus®)Drug: Inhaled Human Insulin (Exubera®)
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 261
- Registration Number
- NCT00391027
- Locations
- 🇨🇭
Pfizer Investigational Site, St. Gallen, Switzerland
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 975
- Registration Number
- NCT00391196
- Locations
- 🇬🇧
Pfizer Investigational Site, Luton, United Kingdom
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 422
- Registration Number
- NCT00389519
- Locations
- 🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇦🇷Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina
🇦🇷Hospital General Interzonal "Dr. José Penna", Buenos Aires, Argentina
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00389441
- Locations
- 🇬🇧
Pfizer Investigational Site, Glasgow, United Kingdom
Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents
- Conditions
- Healthy
- Interventions
- Biological: rLP2086
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 127
- Registration Number
- NCT00387725
- Locations
- 🇦🇺
Royal Children's Hospital, Herston, Queensland, Australia
🇦🇺Department of Paediatrics and Child Health, Woden, Australia
🇦🇺National Centre for Immunisation, Westmead, Australia
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 638
- Registration Number
- NCT00384033
- Locations
- 🇺🇸
Pfizer Investigational Site, Brown Deer, Wisconsin, United States
Methods Study to Characterize Early Indicators of Weight Loss in People
- Conditions
- Obesity
- Interventions
- Behavioral: caloric restriction - 10%Behavioral: caloric restriction - 25%Behavioral: caloric restriction - 50%Behavioral: caloric restriction - Control
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2009-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT00383253
- Locations
- 🇦🇺
Pfizer Investigational Site, North Adelaide, South Australia, Australia
An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 305
- Registration Number
- NCT00383188
- Locations
- 🇧🇷
Hospital Heliópolis - PAM, São Paulo, SP, Brazil
🇨🇿NZZ Bormed, s.r.o., Ostrava - Trebovice, Czechia
🇮🇳Department of Rheumatology, CARE Hospital, Hyderabad, Andhra Pradesh, India
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
- Conditions
- Coronary Arteriosclerosis
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00380939
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States